Theolytics Appoints David Apelian as CEO Amidst Clinical Trials Advancement

Portfolio - People | Dec 17, 2024 | oxford sciences innovation

Theolytics, an Oxford-based biotechnology firm specializing in oncolytic immunotherapies, announced the appointment of Dr. David Apelian as its new CEO. Apelian, a veteran in biotechnology with a comprehensive background in virology and immune-oncology, comes to Theolytics at a pivotal moment as the company progresses with its clinical trial for THEO-260, an innovative candidate for ovarian cancer. With over 25 years in leadership roles across both startup and established biotech entities, Apelian brings a wealth of experience that will aid Theolytics in achieving its strategic and operational goals. Theolytics is known for its cutting-edge approach to developing targeted immunotherapies for cancer treatment, backed by prominent investors like Oxford Science Enterprises and M Ventures.

Sectors

Biotechnology
Pharmaceuticals

Geography

United Kingdom – Theolytics is based in Oxford, UK, highlighting its geographical focus.

Industry

Biotechnology – Theolytics operates in the biotechnology sector developing oncolytic immunotherapies for cancer treatment.
Pharmaceuticals – The article relates to drug development and clinical trials, which are key activities in the pharmaceutical industry.

Financials

Participants

Name	Role	Type	Description
Theolytics	Target Company	Company	A clinical-stage biotechnology company focused on developing oncolytic immunotherapies.
David Apelian	Chief Executive Officer	Person	Appointed as CEO of Theolytics with over 25 years of experience in the biotechnology industry.
Oxford Science Enterprises	Investor	Company	An investor in Theolytics, supporting biotech innovations.
M Ventures	Investor	Company	An investor in Theolytics, specializing in backing life sciences.
Margaret Duffy	Chief Scientific Officer and Co-founder	Person	CSO of Theolytics, overseeing scientific development and operations.